QSAR and flexible docking studies of some aldose reductase inhibitors obtained from natural origin

Medicinal Chemistry Research

Volumn 21, Issue 8, 2012, Pages 1665-1676

  Jain, Shailesh V ^a   Bhadoriya, Kamlendra S ^a   Bari, Sanjaykumar B ^a  

^a R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Aldose reductase; Flexible docking study; QSAR; VLife MDS

Indexed keywords

ALDOSE REDUCTASE INHIBITOR;

ARTICLE; BINDING SITE; DRUG DESIGN; ENZYME BINDING; IN VITRO STUDY; MOLECULAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84866099857     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9681-6     Document Type: Article

References (18)

1. Asano T et al (2002) Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. J Diabetes Complicat 16: 133-138
2. Casellini Carolina M, Vinik Aaron I (2006) Recent advances in the treatment of diabetic neuropathy. Curr Opinion Endo Diabetes 13:147-153
3. Crabbe C, James M (2003) Aldose reductase and the importance of experimental design. Biochem Soc Trans 31:1367-1371
4. Eastman RC, Siebert CW, Harris M, Gorden P (1993) Clinical review 51: implications of the diabetes control and complications trial. Clin Endocrinol Metab 77:1105-1109
5. Fuente JA, Manzanaro S (2003) Aldose reductase inhibitors from natural sources. Nat Prod Rep 20:243-251
6. Jain SV, Sonawane LV, Patil RR, Bari SB (2011) Pharmacophore modeling of some novel indole β-diketo acid and coumarinbased derivatives as HIV integrase inhibitors. Med Chem Res. doi:10.1007/s00044-010-9520-1
7. James M, Crabbe C (1991) Aldose reductase inhibitors and cataract. Int Ophthalmol 15:25-36
8. Kador PF, Kinoshita JH, Sharpless NE (1985) Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. JMed Chem 28:841-857
9. Kawamura M, Hamanaka N (1997) Development of epalrestat (Kinedak®) aldose reductase inhibitor. J Synth Org Chem Jpn 37:651-657
10. Lorenzi M et al (2007) The polyol pathway as mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res 10:1-10
11. Miyamoto S (2002) Molecular modeling and structure-based drug discovery studies of aldose reductase inhibitors. Chem-Bio Inform J 2:74-85
12. Molitch ME et al (2003) American diabetes association: diabetic nephropathy. Diabetes Care 26:S94-S98
13. Nishimura CY (1998) Aldose Reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 50:21-33
14. Preifer MA, Schumer MP, Gelber DA (1997) Aldose reductase inhibitors: the end of an era or the need for different trial designs. Diabetes 46:S82-S89
15. Saraswat M et al (2008) Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Asia Pac J Clin Nutr 17:558-565
16. Srivastava SK, Ramana KV, Bhatnagar A (2005) Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 26:380-392
17. Vengurlekar S, Sharma R, Trivedi P (2009) Two-and three-dimensional QSAR studies on benzyl amide-ketoacid inhibitors of HIV integrase and their reduced analogues. Med Chem Res. doi: 10.1007/s00044-009-9256-y
18. Wrobel J (1991) Syntheses of tolrestat analogues containing Identification of potent, orally active 2-fluoro derivatives. J Med Chem 34:2504-2520